Participate in Research

Luminesce
Protocol: STUDY00005812
Full Title
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
Description
The purpose of this study is to evaluate the effects, good or bad, of subcutaneous (under the skin) injections of satralizumab in combination with current treatment in patients with generalized Myasthenia Gravis.
Compensation: No
Eligibility
Age Group: Adults
Principal Investigator: GIL WOLFE
ClinicalTrials.gov: Open Study
Contact(s)
KARA PATRICK
kpatrick@buffalo.edu
+1 716-829-5037
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.

Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact ctsiresearch@buffalo.edu.